Cargando…

Dexmedetomidine Activates Akt, STAT6 and IRF4 Modulating Cytoprotection and Macrophage Anti-Inflammatory Phenotype Against Acute Lung Injury in vivo and in vitro

PURPOSE: This study aims to investigate the cytoprotective and anti-inflammatory effects of an α(2)-adrenoreceptor (α(2)-AR) agonist, dexmedetomidine (Dex), on lipopolysaccharides (LPS)-induced acute lung injury and underlying mechanisms with focus on alveolar macrophage polarization modulation. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Qian, Qin, Zhigang, Sun, Yibing, Liu, Xiangfeng, Pac Soo, Aurelie, Chang, Enqiang, Sun, Qizhe, Yi, Bin, Wang, Dong-Xin, Zhao, Hailin, Ma, Daqing, Gu, Jianteng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056075/
https://www.ncbi.nlm.nih.gov/pubmed/35502244
http://dx.doi.org/10.2147/JIR.S357012
_version_ 1784697553301798912
author Chen, Qian
Qin, Zhigang
Sun, Yibing
Liu, Xiangfeng
Pac Soo, Aurelie
Chang, Enqiang
Sun, Qizhe
Yi, Bin
Wang, Dong-Xin
Zhao, Hailin
Ma, Daqing
Gu, Jianteng
author_facet Chen, Qian
Qin, Zhigang
Sun, Yibing
Liu, Xiangfeng
Pac Soo, Aurelie
Chang, Enqiang
Sun, Qizhe
Yi, Bin
Wang, Dong-Xin
Zhao, Hailin
Ma, Daqing
Gu, Jianteng
author_sort Chen, Qian
collection PubMed
description PURPOSE: This study aims to investigate the cytoprotective and anti-inflammatory effects of an α(2)-adrenoreceptor (α(2)-AR) agonist, dexmedetomidine (Dex), on lipopolysaccharides (LPS)-induced acute lung injury and underlying mechanisms with focus on alveolar macrophage polarization modulation. METHODS: C57BL/6 mice were intraperitoneally injected LPS (10 mg/kg) with or without Dex (25 µg/kg) and/or α(2)-AR antagonist atipamezole (Atip, 500 µg/kg). Lung tissues were then analysed to determine injuries. In vitro, human pulmonary epithelial cells (A549) and mice alveolar macrophages (MH-S) were exposed to LPS (10 ng/mL) with or without different concentrations of Dex (0.1–100 nM). Alveolar macrophage polarization, NLRP3 inflammasome activation and inflammatory responses were determined. PTEN/Akt signaling and its downstream transcriptional factors as targets for macrophage polarization were assessed. RESULTS: Dex treatment significantly reduced pro-inflammatory M1 macrophage polarization and NLRP3 inflammasome activation in the lungs relative to the mice treated with LPS. The similar pattern reduction of NLRP3 inflammasome activation by Dex was also found in A549 cells. Atip partly reversed the anti-inflammatory effects of Dex. In cultured alveolar macrophages, Dex reduced LPS-mediated expression of IL-1, −6 and TNF-α receptors while promoting alveolar macrophages differentiation towards a M2 anti-inflammatory phenotype. Additionally, LPS increased Akt signaling activation in a time-dependent manner, which was further activated by Dex via inhibiting phosphatase and tensin homolog (PTEN). The action of Dex on Akt signaling shifted alveolar macrophages from M1 to M2 phenotype through increasing STAT6 and IRF4 transcriptional factors. CONCLUSION: Dex protected against LPS-induced lung injury and suppressed LPS-induced pulmonary inflammatory responses by attenuating the NLRP3 inflammasome activation and promoting anti-inflammatory M2 macrophage polarization.
format Online
Article
Text
id pubmed-9056075
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-90560752022-05-01 Dexmedetomidine Activates Akt, STAT6 and IRF4 Modulating Cytoprotection and Macrophage Anti-Inflammatory Phenotype Against Acute Lung Injury in vivo and in vitro Chen, Qian Qin, Zhigang Sun, Yibing Liu, Xiangfeng Pac Soo, Aurelie Chang, Enqiang Sun, Qizhe Yi, Bin Wang, Dong-Xin Zhao, Hailin Ma, Daqing Gu, Jianteng J Inflamm Res Original Research PURPOSE: This study aims to investigate the cytoprotective and anti-inflammatory effects of an α(2)-adrenoreceptor (α(2)-AR) agonist, dexmedetomidine (Dex), on lipopolysaccharides (LPS)-induced acute lung injury and underlying mechanisms with focus on alveolar macrophage polarization modulation. METHODS: C57BL/6 mice were intraperitoneally injected LPS (10 mg/kg) with or without Dex (25 µg/kg) and/or α(2)-AR antagonist atipamezole (Atip, 500 µg/kg). Lung tissues were then analysed to determine injuries. In vitro, human pulmonary epithelial cells (A549) and mice alveolar macrophages (MH-S) were exposed to LPS (10 ng/mL) with or without different concentrations of Dex (0.1–100 nM). Alveolar macrophage polarization, NLRP3 inflammasome activation and inflammatory responses were determined. PTEN/Akt signaling and its downstream transcriptional factors as targets for macrophage polarization were assessed. RESULTS: Dex treatment significantly reduced pro-inflammatory M1 macrophage polarization and NLRP3 inflammasome activation in the lungs relative to the mice treated with LPS. The similar pattern reduction of NLRP3 inflammasome activation by Dex was also found in A549 cells. Atip partly reversed the anti-inflammatory effects of Dex. In cultured alveolar macrophages, Dex reduced LPS-mediated expression of IL-1, −6 and TNF-α receptors while promoting alveolar macrophages differentiation towards a M2 anti-inflammatory phenotype. Additionally, LPS increased Akt signaling activation in a time-dependent manner, which was further activated by Dex via inhibiting phosphatase and tensin homolog (PTEN). The action of Dex on Akt signaling shifted alveolar macrophages from M1 to M2 phenotype through increasing STAT6 and IRF4 transcriptional factors. CONCLUSION: Dex protected against LPS-induced lung injury and suppressed LPS-induced pulmonary inflammatory responses by attenuating the NLRP3 inflammasome activation and promoting anti-inflammatory M2 macrophage polarization. Dove 2022-04-26 /pmc/articles/PMC9056075/ /pubmed/35502244 http://dx.doi.org/10.2147/JIR.S357012 Text en © 2022 Chen et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Chen, Qian
Qin, Zhigang
Sun, Yibing
Liu, Xiangfeng
Pac Soo, Aurelie
Chang, Enqiang
Sun, Qizhe
Yi, Bin
Wang, Dong-Xin
Zhao, Hailin
Ma, Daqing
Gu, Jianteng
Dexmedetomidine Activates Akt, STAT6 and IRF4 Modulating Cytoprotection and Macrophage Anti-Inflammatory Phenotype Against Acute Lung Injury in vivo and in vitro
title Dexmedetomidine Activates Akt, STAT6 and IRF4 Modulating Cytoprotection and Macrophage Anti-Inflammatory Phenotype Against Acute Lung Injury in vivo and in vitro
title_full Dexmedetomidine Activates Akt, STAT6 and IRF4 Modulating Cytoprotection and Macrophage Anti-Inflammatory Phenotype Against Acute Lung Injury in vivo and in vitro
title_fullStr Dexmedetomidine Activates Akt, STAT6 and IRF4 Modulating Cytoprotection and Macrophage Anti-Inflammatory Phenotype Against Acute Lung Injury in vivo and in vitro
title_full_unstemmed Dexmedetomidine Activates Akt, STAT6 and IRF4 Modulating Cytoprotection and Macrophage Anti-Inflammatory Phenotype Against Acute Lung Injury in vivo and in vitro
title_short Dexmedetomidine Activates Akt, STAT6 and IRF4 Modulating Cytoprotection and Macrophage Anti-Inflammatory Phenotype Against Acute Lung Injury in vivo and in vitro
title_sort dexmedetomidine activates akt, stat6 and irf4 modulating cytoprotection and macrophage anti-inflammatory phenotype against acute lung injury in vivo and in vitro
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056075/
https://www.ncbi.nlm.nih.gov/pubmed/35502244
http://dx.doi.org/10.2147/JIR.S357012
work_keys_str_mv AT chenqian dexmedetomidineactivatesaktstat6andirf4modulatingcytoprotectionandmacrophageantiinflammatoryphenotypeagainstacutelunginjuryinvivoandinvitro
AT qinzhigang dexmedetomidineactivatesaktstat6andirf4modulatingcytoprotectionandmacrophageantiinflammatoryphenotypeagainstacutelunginjuryinvivoandinvitro
AT sunyibing dexmedetomidineactivatesaktstat6andirf4modulatingcytoprotectionandmacrophageantiinflammatoryphenotypeagainstacutelunginjuryinvivoandinvitro
AT liuxiangfeng dexmedetomidineactivatesaktstat6andirf4modulatingcytoprotectionandmacrophageantiinflammatoryphenotypeagainstacutelunginjuryinvivoandinvitro
AT pacsooaurelie dexmedetomidineactivatesaktstat6andirf4modulatingcytoprotectionandmacrophageantiinflammatoryphenotypeagainstacutelunginjuryinvivoandinvitro
AT changenqiang dexmedetomidineactivatesaktstat6andirf4modulatingcytoprotectionandmacrophageantiinflammatoryphenotypeagainstacutelunginjuryinvivoandinvitro
AT sunqizhe dexmedetomidineactivatesaktstat6andirf4modulatingcytoprotectionandmacrophageantiinflammatoryphenotypeagainstacutelunginjuryinvivoandinvitro
AT yibin dexmedetomidineactivatesaktstat6andirf4modulatingcytoprotectionandmacrophageantiinflammatoryphenotypeagainstacutelunginjuryinvivoandinvitro
AT wangdongxin dexmedetomidineactivatesaktstat6andirf4modulatingcytoprotectionandmacrophageantiinflammatoryphenotypeagainstacutelunginjuryinvivoandinvitro
AT zhaohailin dexmedetomidineactivatesaktstat6andirf4modulatingcytoprotectionandmacrophageantiinflammatoryphenotypeagainstacutelunginjuryinvivoandinvitro
AT madaqing dexmedetomidineactivatesaktstat6andirf4modulatingcytoprotectionandmacrophageantiinflammatoryphenotypeagainstacutelunginjuryinvivoandinvitro
AT gujianteng dexmedetomidineactivatesaktstat6andirf4modulatingcytoprotectionandmacrophageantiinflammatoryphenotypeagainstacutelunginjuryinvivoandinvitro